NATEGLINIDE

Nateglinide 120mg, Oral tablet

Alcohol

· Severity: Major

· Notes for Consumers: Do not drink alcohol while taking this medication. Drinking alcohol while taking this medication increases the risk for a dangerous decrease in your blood sugar (hypoglycemia). Contact your care team if you experience tremors or shaking, anxiety, sweating, cold or clammy skin, confusion, dizziness, or a rapid heartbeat.

· Notes for Professionals: Patients should be advised to avoid or limit alcohol ingestion when treated with meglitinides. Alcohol ingestion increases hypoglycemic risk. In some patients, hypoglycemia can be prolonged. Patients should be educated regarding the signs, symptoms, and self-management of delayed hypoglycemia after drinking alcohol, especially when using meglitinides. The importance of glucose monitoring after drinking alcoholic beverages to reduce hypoglycemia risk should be emphasized.

Nateglinide 120mg, Oral tablet

Grapefruit juice

· Severity: Major

· Notes for Consumers: Do not drink grapefruit juice or eat grapefruit while taking this medication. Grapefruit may alter the effects of your medication. Serious side effects may occur. Contact your care team right away if you experience new or worsening side effects.

· Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during nateglinide treatment due to the risk of increased nateglinide exposure and adverse reactions. Nateglinide is a CYP2C9 substrate and grapefruit juice is a CYP2C9 inhibitor.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>